Tags

Type your tag names separated by a space and hit enter

Psoriatic arthritis: clinical improvement and correlation with hormone axes in etanercept-treated patients.
Ann N Y Acad Sci. 2010 Apr; 1193:176-8.AN

Abstract

In a chronic inflammatory disease, such as rheumatoid arthritis (RA), the hypothalamic-pituitary-adrenal axis is altered in three ways: (1) the inflammation-related spontaneous and stimulated secretion of cortisol is inadequate; (2) the inflammation-related secretion of adrenocorticotropic hormone (ACTH) is low; and (3) the levels of adrenal androgens decrease. In patients with RA, long-term therapy with anti-TNF therapy sensitizes the pituitary gland and improves adrenal androgen secretion. We have recently found that the mean serum levels of ACTH, cortisol, 17-hydroxyprogesterone (17OHP), and androstenedione (ASD) in 11 prednisolone-naïve patients with psoriatic arthritis did not markedly change during 12 weeks of etanercept treatment, nor did the serum cortisol/ACTH ratio. However, the greater increase in serum cortisol in comparison with serum 17OHP or ASD was related to clinical improvement, which indicates that the improvement was more related to the higher cortisol levels.

Authors+Show Affiliations

Rheumatology Unit, University Hospital L. Sacco, Milan, Italy.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

20398026

Citation

Atzeni, Fabiola, et al. "Psoriatic Arthritis: Clinical Improvement and Correlation With Hormone Axes in Etanercept-treated Patients." Annals of the New York Academy of Sciences, vol. 1193, 2010, pp. 176-8.
Atzeni F, Straub RH, Cutolo M, et al. Psoriatic arthritis: clinical improvement and correlation with hormone axes in etanercept-treated patients. Ann N Y Acad Sci. 2010;1193:176-8.
Atzeni, F., Straub, R. H., Cutolo, M., & Sarzi-Puttini, P. (2010). Psoriatic arthritis: clinical improvement and correlation with hormone axes in etanercept-treated patients. Annals of the New York Academy of Sciences, 1193, 176-8. https://doi.org/10.1111/j.1749-6632.2009.05363.x
Atzeni F, et al. Psoriatic Arthritis: Clinical Improvement and Correlation With Hormone Axes in Etanercept-treated Patients. Ann N Y Acad Sci. 2010;1193:176-8. PubMed PMID: 20398026.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Psoriatic arthritis: clinical improvement and correlation with hormone axes in etanercept-treated patients. AU - Atzeni,Fabiola, AU - Straub,Rainer H, AU - Cutolo,Maurizio, AU - Sarzi-Puttini,Piercarlo, PY - 2010/4/20/entrez PY - 2010/4/20/pubmed PY - 2010/5/19/medline SP - 176 EP - 8 JF - Annals of the New York Academy of Sciences JO - Ann N Y Acad Sci VL - 1193 N2 - In a chronic inflammatory disease, such as rheumatoid arthritis (RA), the hypothalamic-pituitary-adrenal axis is altered in three ways: (1) the inflammation-related spontaneous and stimulated secretion of cortisol is inadequate; (2) the inflammation-related secretion of adrenocorticotropic hormone (ACTH) is low; and (3) the levels of adrenal androgens decrease. In patients with RA, long-term therapy with anti-TNF therapy sensitizes the pituitary gland and improves adrenal androgen secretion. We have recently found that the mean serum levels of ACTH, cortisol, 17-hydroxyprogesterone (17OHP), and androstenedione (ASD) in 11 prednisolone-naïve patients with psoriatic arthritis did not markedly change during 12 weeks of etanercept treatment, nor did the serum cortisol/ACTH ratio. However, the greater increase in serum cortisol in comparison with serum 17OHP or ASD was related to clinical improvement, which indicates that the improvement was more related to the higher cortisol levels. SN - 1749-6632 UR - https://www.unboundmedicine.com/medline/citation/20398026/Psoriatic_arthritis:_clinical_improvement_and_correlation_with_hormone_axes_in_etanercept_treated_patients_ L2 - https://doi.org/10.1111/j.1749-6632.2009.05363.x DB - PRIME DP - Unbound Medicine ER -